Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Altman

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
ACS Medicinal Chemistry Letters|June 24, 2015
Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4Jongwon Lim, Michael D Altman, James Baker, et al.
European Journal of Medicinal Chemistry|July 24, 2021
Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancerVladimir Simov, Michael D Altman, Elisabetta Bianchi, et al.
Journal of Biomolecular Screening|July 28, 2016
Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular ContextBryan Severyn, Thi Nguyen, Michael D Altman, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2016
Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitorsJason D Katz, Andrew Haidle, Kaleen K Childers, et al.
Journal of Medicinal Chemistry|February 6, 2013
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-MetAlan B Northrup, Matthew H Katcher, Michael D Altman, et al.
Journal of Medicinal Chemistry|January 28, 2015
Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitorsJ Michael Ellis, Michael D Altman, Alan Bass, et al.
Journal of Medicinal Chemistry|April 2, 2021
Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ ImmunomodulatorsJoey L Methot, Hua Zhou, Meredeth A McGowan, et al.
ACS Medicinal Chemistry Letters|January 17, 2024
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose ProjectionsH Marie Loughran, Kathy M Schirripa, Anthony J Roecker, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2017
Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammationGraham F Smith, Michael D Altman, Brian Andresen, et al.
ACS Medicinal Chemistry Letters|February 16, 2023
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's DiseaseAnthony J Roecker, Kathy M Schirripa, H Marie Loughran, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
ACS Medicinal Chemistry Letters|June 24, 2015
Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4Jongwon Lim, Michael D Altman, James Baker, et al.
European Journal of Medicinal Chemistry|July 24, 2021
Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancerVladimir Simov, Michael D Altman, Elisabetta Bianchi, et al.
Journal of Biomolecular Screening|July 28, 2016
Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular ContextBryan Severyn, Thi Nguyen, Michael D Altman, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2016
Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitorsJason D Katz, Andrew Haidle, Kaleen K Childers, et al.
Journal of Medicinal Chemistry|February 6, 2013
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-MetAlan B Northrup, Matthew H Katcher, Michael D Altman, et al.
Journal of Medicinal Chemistry|January 28, 2015
Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitorsJ Michael Ellis, Michael D Altman, Alan Bass, et al.
Journal of Medicinal Chemistry|April 2, 2021
Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ ImmunomodulatorsJoey L Methot, Hua Zhou, Meredeth A McGowan, et al.
ACS Medicinal Chemistry Letters|January 17, 2024
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose ProjectionsH Marie Loughran, Kathy M Schirripa, Anthony J Roecker, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2017
Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammationGraham F Smith, Michael D Altman, Brian Andresen, et al.
ACS Medicinal Chemistry Letters|February 16, 2023
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's DiseaseAnthony J Roecker, Kathy M Schirripa, H Marie Loughran, et al.
Pageof 5